SEAGEN
Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a... humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.
SEAGEN
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1998-01-01
Address:
Bothell, Washington, United States
Country:
United States
Website Url:
http://www.seagen.com
Total Employee:
1001+
Status:
Active
Contact:
6192707227
Email Addresses:
[email protected]
Total Funding:
1.74 B USD
Technology used in webpage:
Content Delivery Network IPv6 Microsoft Azure DNS ReCAPTCHA V2 Microsoft ASP.NET Ajax Google Cloud Global Multi-Region Google Analytics IP Anonymization Google Cloud CDN Level 3 Communications
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-01-31 | Cascadian Therapeutics | Cascadian Therapeutics acquired by Seagen | 614 M USD |
Investors List
Merck
Merck investment in Post-IPO Equity - Seagen
Takeda
Takeda investment in Post-IPO Equity - Seagen
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Seagen
Sofinnova Investments
Sofinnova Investments investment in Venture Round - Seagen
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2015-06-11 | Cogent Biosciences | Seagen investment in Series B - Cogent Biosciences | 65 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | Seagen Appoints Lee Heeson as Executive Vice President, Commercial International |
Official Site Inspections
http://www.seagen.com Semrush global rank: 746.98 K Semrush visits lastest month: 54.08 K
- Host name: 172.64.153.181
- IP address: 172.64.153.181
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
